- Home
- / Kyowa Kirin
Kyowa Kirin
Stock Price
$18
2023-09-25
Market Capitalization
$9.7 B
2023-09-25
Revenue
¥398.4 B
FY, 2022
Kyowa Kirin Summary
Company Summary
- Overview
- Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. It specializes in therapeutic antibodies, small molecule drugs, therapeutic nucleic acids, and regenerative medicine. The company was formed as a result of a merger between Kyowa Hakko and Kirin Pharma.
- Type
- Public
- Status
- Active
- Founded
- 2008
- HQ
- Tokyo, JP | view all locations
- Website
- https://www.kyowakirin.com
- Cybersecurity rating
Table of Contents
Key People
Yutaka Osawa, Representative Director Executive Vice President
LocationsView all
31 locations detected
Tokyo, Tokyo HQ
Japan
Otemachi Financial City Grand Cube, 1-9-2 Otemachi
Bedminster, NJ
United States
135 Route 202/206, Suite 6
Princeton, NJ
United States
212 Carnegie Center Dr Suite 400
San Diego, CA
United States
9420 Athena Cir, La Jolla
Sydney, NSW
Australia
68 York St
Shanghai, Shang Hai Shi
China
970 Longdong Road,Pilot Free Trade Zone
Kyowa Kirin Financials
Summary Financials
- Revenue (Q2, 2023)
- ¥105.7B
- Gross profit (Q2, 2023)
- ¥80.3B
- Net income (Q2, 2023)
- ¥8.9B
- Cash (Q2, 2023)
- ¥372.1B
- EBIT (Q2, 2023)
- ¥9.2B
- Enterprise value
- ($362.5B)